Saturday, 31 October 2026European Markets

INAPA-INV.P.GESTAO Stock Rises By 15% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of INAPA-INV.P.GESTAO (PSI: INA.LS) jumped by a staggering 15.38% in 5 sessions from €0.05 to €0.06 at 16:25 EST on Friday, after two sequential sessions in a row of losses. PSI is jumping 0.26% to €5,996.85, following the last session's upward trend.

About INAPA-INV.P.GESTAO

Inapa - Investimentos, Participações e Gestão, S.A., through its subsidiaries, distributes and sells paper products in Portugal. It operates through three segments: Paper Supply, Packaging, and Visual Communication. The company offers coated, uncoated, carbonless, self-adhesive, stock, board, envelopes, and fine papers; graphics consumables, such as inks, cleaning products, additives printing blankets, plates, and varnishes; office papers; and office supplies. It also provides boxes, films, tapes, fillers, bags, labels, fillings, and equipment, as well as customized solutions and personalized packaging. In addition, the company offers printing products and services for a large format of digital printing, including printers, inks/toners, media, software, and technical assistance, as well as logistic services. Inapa - Investimentos, Participações e Gestão, S.A. was founded in 1965 and is headquartered in Lisbon, Portugal.

Earnings Per Share

As for profitability, INAPA-INV.P.GESTAO has a trailing twelve months EPS of €-0.024.

More news about INAPA-INV.P.GESTAO (INA.LS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com